ASCELIA PHARMA AB
Research ASCELIA PHARMA AB (7ZA) on Bullrun: market cap EUR 26.77M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker7ZA
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 26.77M
- Financial periodFY2024
- Net income-SEK 80.03M
- Free cash flow-SEK 62.84M
Valuation Snapshot
latest market cap is EUR 26.77M.
About ASCELIA PHARMA AB
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc.
Frequently asked questions
What is ASCELIA PHARMA AB's market cap?
ASCELIA PHARMA AB's market capitalization is EUR 26.77M.
What does ASCELIA PHARMA AB do?
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver;